Patents by Inventor Christopher D. Snow

Christopher D. Snow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12606850
    Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.
    Type: Grant
    Filed: March 4, 2024
    Date of Patent: April 21, 2026
    Assignee: Sasya, Inc.
    Inventors: Goutham Vemuri, Christopher Lindsay, Kevin Roberg-Perez, Christopher D. Snow, Elizabeth A. Cameron
  • Patent number: 12234495
    Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using at least one non-natural enzyme. The non-natural enzyme for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural enzyme having one or more modifications of substrate-specificity positions. The non-natural enzyme can be expressed in a microorganism, such as a yeast or bacteria, wherein the microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. Alternatively, the non-natural enzyme can be a ?HIV synthase used to produce ?HIV in a cell-free environment. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural enzyme prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.
    Type: Grant
    Filed: April 6, 2022
    Date of Patent: February 25, 2025
    Assignee: Sasya Inc.
    Inventors: Goutham Vemuri, Christopher Lindsay, Kevin Roberg-Perez, Christopher D. Snow, Elizabeth A. Cameron
  • Publication number: 20250002949
    Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.
    Type: Application
    Filed: March 4, 2024
    Publication date: January 2, 2025
    Inventors: Goutham Vemuri, Christopher Lindsay, Kevin Roberg-Perez, Christopher D. Snow, Elizabeth A. Cameron
  • Patent number: 11920177
    Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.
    Type: Grant
    Filed: April 6, 2022
    Date of Patent: March 5, 2024
    Assignee: SASYA INC.
    Inventors: Goutham Vemuri, Christopher Lindsay, Kevin Roberg-Perez, Christopher D. Snow, Elizabeth A. Cameron
  • Publication number: 20230399637
    Abstract: The present disclosure relates to data storage systems and methods of making thereof. Aspects of the disclosure further relate to engineered porous protein crystals that bind and adsorb guest information storage mediums such as DNA.
    Type: Application
    Filed: November 10, 2021
    Publication date: December 14, 2023
    Inventors: Christopher D. SNOW, Julius D. STUART, Rebekah C. KADING, Lyndsey I. GRAY, Daniel A. HARTMAN
  • Publication number: 20220325304
    Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using at least one non-natural enzyme. The non-natural enzyme for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural enzyme having one or more modifications of substrate-specificity positions. The non-natural enzyme can be expressed in a microorganism, such as a yeast or bacteria, wherein the microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. Alternatively, the non-natural enzyme can be a ?HIV synthase used to produce ?HIV in a cell-free environment. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural enzyme prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.
    Type: Application
    Filed: April 6, 2022
    Publication date: October 13, 2022
    Inventors: Goutham Vemuri, Christopher Lindsay, Kevin Roberg-Perez, Christopher D. Snow, Elizabeth A. Cameron
  • Publication number: 20220315954
    Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.
    Type: Application
    Filed: April 6, 2022
    Publication date: October 6, 2022
    Inventors: Goutham Vemuri, Christopher Lindsay, Kevin Roberg-Perez, Christopher D. Snow, Elizabeth A. Cameron
  • Patent number: 10590176
    Abstract: The present disclosure provides compositions and methods for preparing engineered porous protein crystals comprising at least one guest molecule.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: March 17, 2020
    Assignee: Colorado State University Research Foundation
    Inventors: Christopher D. Snow, Thaddaus R. Huber
  • Publication number: 20170362282
    Abstract: The present disclosure provides compositions and methods for preparing engineered porous protein crystals comprising at least one guest molecule.
    Type: Application
    Filed: June 20, 2017
    Publication date: December 21, 2017
    Applicant: Colorado State University Research Foundation
    Inventors: Christopher D. Snow, Thaddaus R. Huber